ReviewCurrent osteoporosis reports2026
Angiogenic and Osteogenic Strategies for Skeletal Regeneration in Aging.
Review in Current osteoporosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAging disrupts skeletal homeostasis, resulting in impaired fracture healing, increased risk of nonunion, and reduced regenerative capacity. These deficits are associated with dysregulated inflammation, impaired angiogenesis, and reduced osteogenesis, while current treatments remain limited in aged populations. This review examines emerging regenerative approaches that target both vascular and osteogenic dysfunction during skeletal repair. RECENT
findingsRecent studies have emphasized the importance of angiogenic-osteogenic coupling in successful bone repair. Endothelial progenitor cells (EPCs) promote neovascularization, improve vascular function, and support osteogenesis, while EPC-derived extracellular vesicles (EV), particularly exosomes, enhance intercellular communication, angiogenesis, and tissue repair with fewer limitations than cell-based therapies. In addition, signal transducer and activator of transcription 3 (STAT3) has been identified as a key regulator of osteoblast function, angiogenesis, and bone remodeling, making it an attractive molecular target for enhancing skeletal regeneration. EPC-based therapies, exosome-mediated interventions, and modulation of STAT3 signaling are promising strategies to enhance skeletal regeneration by addressing both vascular dysfunction and impaired osteogenesis. Continued investigation into the mechanisms, safety, and translational potential of these approaches will be critical for advancing regenerative therapies for age-related skeletal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.